Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery
platforms, today announced its development of additional enhancements for its
industry-leading DehydraTECH(TM) platform that delivers THC onset of action in
less than 10 minutes in human pilot testing. According to the update,
volunteers in recent human subjective pilot tests reported onset in less than
10 minutes from edibles formulated with this latest DehydraTECH innovation.
This enhanced version of the delivery platform shows onset that is roughly
twice as fast as traditional DehydraTECH and four to six times faster than
generic industry formulations.
To view the full press release, visit http://ibn.fm/2482T
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bioabsorption, reduces time of onset and masks unwanted tastes for orally administered
bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has
licensed DehydraTECH to multiple companies in the cannabis industry for use in
cannabinoid beverages, edibles and oral products, as well as to a world-leading
tobacco producer for the development of smokeless, oral-based nicotine
products. Lexaria operates a licensed, in-house research laboratory and holds a
robust intellectual property portfolio with 16 patents granted and over 60
patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
